Salarius obtains dose-escalation milestones for its Seclidemstat trial
Category: #health  By Mateen Dalal  Date: 2019-09-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Salarius obtains dose-escalation milestones for its Seclidemstat trial

sarcoma is a type of bone cancer that can also appear in fat, muscle, deep skin tissues, blood vessels, tendons, ligaments and cartilage. Moreover, there are over 70 types of sarcoma, with each treatment varying from the other, depending on various factors like location and type.

Salarius Pharmaceuticals, Inc., recently made some significant developments in this regard, announcing that the Safety Review Committees monitoring the Phase 1 trials of Seclidemstat in patients with AST (advanced solid tumors) and the Phase 1/2 clinical trial of Seclidemstat in Ewing sarcoma have cleared the developments of each trial to the fourth stage of dosing. 

According to reliable sources, both the clinical studies were designed as a dose-finding open-label studies to understand the initial safety profile of Seclidemstat and establish the maximum tolerated dose (MTD). 

Additionally, Seclidemstat, which was administered every day as an oral tablet, with each test group getting a heightened dose of study drug, will later be administered to a bigger group of patients so as to confirm its safety profile. Reportedly the firm aims to gather additional information regarding potential preliminary efficacy and pharmacokinetics.

Speaking on the development, David Arthur, President and Chief Executive Officer, Salarius, said that an approval from the Safety Review Committees to go ahead with a higher dosing cohort marks a significant landmark for the ongoing clinical studies, as well as the company.

Arthur further added, ultimately, the endpoint of these studies is to identify the ideal dose of Seclidemstat, as well as establishing the drug’s safety parameters. Evidently, according to the current estimates the company is on track to achieve MTD by early next year and intends to report initial patient data in 2020.

Change in Management

Meanwhile, the company recently made headlines, when it announced its new Chief Business Officer and Executive Vice President Finance.

According to the latest reports, Scott Jordan will fulfill the role of Chief Business Officer while Mark Rosenblum will act as the Executive Vice President Finance and also fill the shoes of Interim Chief Financial Officer.

Reportedly, the move plans to improve the company’s focus on strategic value creation and financial operations while its clinical programs in advanced solid tumors and Ewing sarcoma advance towards achieving potential data milestones by 2020.

 

Source Credit: http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-achieves-dose-escalation-milestones

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

UK MHRA assigns PIM status to ReveraGen’s Vamorolone as a DMD therapy
UK MHRA assigns PIM status to ReveraGen’s Vamorolone as a DMD therapy
By Mateen Dalal

Duchenne muscular dystrophy (DMD) approximately affects 1 in every 3,500 male births every year in the world. several biopharmaceutical and biotechnology firms across the globe are increasingly working towards the discovery and development of novel t...

ASM announces launch of Checksome™ to advance patient safety
ASM announces launch of Checksome™ to advance patient safety
By Mateen Dalal

Blockchain has grown to become an ingenious invention and has built the backbone for a new type of internet, which is originally devised for digital currencies and bitcoin. However, several tech companies have found other potential for this technolog...

Abeona Therapeutics unveils positive data from trial for RDEB therapy
Abeona Therapeutics unveils positive data from trial for RDEB therapy
By Mateen Dalal

Various hereditary disorders and diseases are increasingly growing across the world which need to be treated effectively. Global pharmaceutical firms are increasingly working towards finding novel solutions to address the ever-increasing occurrence o...